[ Price : $8.95]
FDA approves Boehringer Ingelheims Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) as treatment...[ Price : $8.95]
Twenty-five bipartisan House representatives urge FDA to create patient-centered policies on compounded hormones that maintain pat...[ Price : $8.95]
Federal Register notice: FDA makes available a final guidance entitled Oncology Drug Products Used with Certain In Vitro Diagnosti...[ Price : $8.95]
Federal Register notice: FDA permanently debars Daylen Diaz from providing services in any capacity to a person that has an approv...[ Price : $8.95]
The Physicians Committee for Responsible Medicine asks FDA to require a notice on all glucagon-like peptide-1 receptor agonists th...[ Price : $8.95]
FDA warns Highland, IL-based Chicago Cornea Consultants about violations in its conduct of two clinical studies with investigation...[ Price : $8.95]
FDA accepts for priority review a bluebird bio BLA for lovotibeglogene autotemcel (lovo-cel), a gene therapy for certain patients ...[ Price : $8.95]
Pieris Pharmaceuticals says its partner AstraZeneca is discontinuing a Phase 2a study of the asthma drug elarekibep.